ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PD-1/CD47 Fusion Protein HX009

Also written as “HX009”, “Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection” and “HX009+IN10018”.

Its studies are mostly in Lymphoma · Biliary Tract Neoplasms, led by 2 companies.

Drug pageAnti-PD-1/CD47 Fusion Protein HX009: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since May 5, 20215 company-led studies, 2 open or runningNext primary completion: Dec 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hangzhou Hanx Biopharmaceuticalsits history only42 open or runningphase 2since May 5, 2021May 5, 2021Dec 31, 2027phase 2 · NCT06708663
Waterstone Hanxbio Ptyits history only10 open or runningphase 1since Aug 28, 2019Aug 28, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 28, 2019First study: phase 1 study in Advanced Solid TumorNew to Waterstone Hanxbio PtyWaterstone Hanxbio Pty · NCT04097769 · 21 enrolled · Australia
  2. May 5, 2021Hangzhou Hanx Biopharmaceuticals’ first study: phase 2 study in Advanced Solid TumorNew to Hangzhou Hanx BiopharmaceuticalsHangzhou Hanx Biopharmaceuticals · NCT04886271 · 20 enrolled · China
  3. Dec 8, 2021Phase 2 study in LymphomaHangzhou Hanx Biopharmaceuticals · NCT05189093 · 48 enrolled · China
  4. Jan 29, 2023Phase 1 study in Advanced Solid TumorsHangzhou Hanx Biopharmaceuticals · NCT05731752 · 80 enrolled · China
  5. Nov 25, 2024Phase 2 study in Biliary Tract NeoplasmsHangzhou Hanx Biopharmaceuticals · NCT06708663 · 124 planned · China

Ahead

  1. Dec 31, 2027Primary completion: phase 2 study in Biliary Tract NeoplasmsHangzhou Hanx Biopharmaceuticals · NCT06708663

TargetBeta

CD47 →PDCD1 →read by rule
“A bispecific antibody fusion protein directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human cell surface antigen CD47, ”NCIt, by rule

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06708663Biliary Tract Neoplasms · China2RecruitingHangzhou Hanx BiopharmaceuticalsDec 31, 2027124
NCT05731752Advanced Solid Tumors · China1Active, not recruitingHangzhou Hanx BiopharmaceuticalsDec 30, 202480
NCT05189093Lymphoma · China2CompletedHangzhou Hanx BiopharmaceuticalsJun 25, 202548
NCT04886271Advanced Solid Tumor · China2CompletedHangzhou Hanx BiopharmaceuticalsJan 12, 202420
NCT04097769Advanced Solid Tumor · Australia1CompletedWaterstone Hanxbio PtyMar 18, 202121

How it is read

Names in the registry

  • “HX009”, 3 entries
  • “Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection”, 1 entry
  • “HX009+IN10018”, 1 entry

Codes read as this program: HX009.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.